Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE A SALZBERG

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1376528943
CMS profile
243136
Location
SUWANEE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$25,152.08

58 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 58 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE A SALZBERG

NPI 1376528943 · CMS profile ID 243136

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

SUWANEE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 58 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376528943?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 58 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376528943?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 58 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376528943?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 58 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1376528943?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

58 matching records · $25,152.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 58 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 58.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $17.0412/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064299 CMS
AbbVie Inc. $15.9512/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108781 CMS
AbbVie Inc. $5.9812/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108779 CMS
AbbVie Inc. $20.2612/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108777 CMS
Janssen Biotech, Inc. $5.0611/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064297 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.5611/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747293479 CMS
AbbVie Inc. $6.8111/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108775 CMS
AbbVie Inc. $17.3211/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108773 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,450.0011/16/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747293477 CMS
AbbVie Inc. $17.9111/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108769 CMS
AbbVie Inc. $13.9111/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108771 CMS
AbbVie Inc. $9.9711/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108767 CMS
AbbVie Inc. $14.8610/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108765 CMS
AbbVie Inc. $5.1610/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108763 CMS
Janssen Biotech, Inc. $1,437.5009/30/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064289 CMS
Celgene Corporation $2,450.0009/24/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727915531 CMS
Daiichi Sankyo Inc. $15.7109/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739499767 CMS
Janssen Biotech, Inc. $21.9609/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064291 CMS
Janssen Scientific Affairs, LLC $860.0009/15/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064319 CMS
AbbVie Inc. $9.4809/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108761 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.1909/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737607423 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.6508/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747293475 CMS
Merck Sharp & Dohme Corporation $13.7708/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747708245 CMS
Janssen Biotech, Inc. $1,437.5008/13/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064287 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.4708/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747293473 CMS
AbbVie Inc. $13.4008/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108759 CMS
Janssen Biotech, Inc. $21.9607/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064293 CMS
PFIZER INC. $15.6407/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743267285 CMS
AbbVie Inc. $13.9107/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108757 CMS
Janssen Biotech, Inc. $16.4707/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064295 CMS
Janssen Biotech, Inc. $1,437.5007/03/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064285 CMS
Alfasigma USA, Inc. $13.7407/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723131975 CMS
Janssen Scientific Affairs, LLC $860.0005/20/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064317 CMS
Janssen Biotech, Inc. $7.4105/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064283 CMS
AbbVie Inc. $8.0105/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108755 CMS
Janssen Scientific Affairs, LLC $1,150.0004/17/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064315 CMS
Janssen Biotech, Inc. $21.7004/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064281 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,610.0003/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747293471 CMS
AbbVie Inc. $5.5503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108753 CMS
PFIZER INC. $4.7902/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743268165 CMS
AbbVie Inc. $3.1402/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722108751 CMS
PFIZER INC. $17.3902/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743268691 CMS
Takeda Pharmaceuticals U.S.A., Inc. $91.7602/18/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747293465 CMS
Takeda Pharmaceuticals U.S.A., Inc. $622.8502/18/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747293467 CMS
Takeda Pharmaceuticals U.S.A., Inc. $79.6502/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747293469 CMS
Janssen Scientific Affairs, LLC $30.5602/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064311 CMS
Janssen Scientific Affairs, LLC $80.4002/13/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064313 CMS
PFIZER INC. $12.1702/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743266913 CMS
Janssen Biotech, Inc. $14.7502/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064279 CMS
Janssen Scientific Affairs, LLC $860.0001/31/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719064301 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $87,088.72 183
PY2020 $25,152.08 58
PY2021 $17,526.51 124
PY2022 $46,620.72 107
PY2023 $41,911.39 77
PY2024 $16,306.24 46
PY2025 $40,647.25 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $35,777.10 3
PY2023 Principal investigator $4,640.61 4
PY2022 Principal investigator $52,325.70 12
PY2021 Principal investigator $131,307.67 47
PY2020 Recipient $7,898.24 3
PY2020 Principal investigator $335,230.92 133
PY2019 Recipient $12,040.75 4
PY2019 Principal investigator $611,218.71 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

96 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Allergan Inc. $8,179.53 12/31/2019 Covered Recipient Physician A 52-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b3, Parallel-Group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 670008783
Recipient Allergan Inc. $2,247.24 12/31/2019 Covered Recipient Physician A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 670008791
Principal investigator 1 Janssen Research & Development, LLC $7,750.00 12/23/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654242507
Principal investigator 1 Janssen Research & Development, LLC $2,993.00 12/23/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 654242509
Principal investigator 1 Gilead Sciences, Inc. $20,734.00 12/18/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 676494325
Principal investigator 1 AbbVie, Inc. $7,560.00 12/05/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-533 No dispute reported 06/30/2026 647584379
Principal investigator 1 AbbVie, Inc. $207.50 12/04/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-430 No dispute reported 06/30/2026 647584377
Principal investigator 1 AbbVie, Inc. $708.75 11/27/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-431 No dispute reported 06/30/2026 647584381
Principal investigator 1 AbbVie, Inc. $350.00 11/21/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
P11-282 No dispute reported 06/30/2026 647584363
Principal investigator 1 PFIZER INC. $682.81 11/06/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 671667679
Principal investigator 1 AbbVie, Inc. $1,020.00 11/04/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-533 No dispute reported 06/30/2026 647584383
Principal investigator 1 AbbVie, Inc. $1,274.48 11/04/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-234 No dispute reported 06/30/2026 647584385
Principal investigator 1 Janssen Research & Development, LLC $19,149.00 10/31/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 654242503
Principal investigator 1 Janssen Research & Development, LLC $9,215.00 10/31/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654242505
Principal investigator 1 Gilead Sciences, Inc. $1,656.00 10/23/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 676494321
Principal investigator 1 Janssen Research & Development, LLC $1,941.00 10/22/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists
Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis No dispute reported 06/30/2026 654243281
Principal investigator 1 Janssen Research & Development, LLC $9,910.00 10/22/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 654243303
Principal investigator 1 Janssen Research & Development, LLC $3,708.00 10/22/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 654243305
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,315.00 10/18/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects with UC No dispute reported 06/30/2026 686168653
Principal investigator 1 Gilead Sciences, Inc. $3,500.00 10/07/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
Phase 2, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Safety and Efficacy of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 676494316
Principal investigator 1 AbbVie, Inc. $7,985.00 10/01/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-675 No dispute reported 06/30/2026 647584373
Principal investigator 1 AbbVie, Inc. $54.00 10/01/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-533 No dispute reported 06/30/2026 647584375
Principal investigator 1 AbbVie, Inc. $3,421.50 09/30/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-234 No dispute reported 06/30/2026 647584369
Principal investigator 1 AbbVie, Inc. $1,354.25 09/30/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-430 No dispute reported 06/30/2026 647584371
Principal investigator 1 Janssen Research & Development, LLC $10,000.00 09/30/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 654242499
Principal investigator 1 PFIZER INC. $682.81 09/25/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 671667673
Principal investigator 1 Genentech, Inc. $1,080.90 09/13/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
OLE No dispute reported 06/30/2026 681115241
Principal investigator 1 PFIZER INC. $29,868.00 09/06/2019 Non-covered Recipient Entity
Atlanta Gastro Specialists
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 671682695
Principal investigator 1 AbbVie, Inc. $207.50 08/30/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-431 No dispute reported 06/30/2026 647584365
Principal investigator 1 Janssen Research & Development, LLC $31,852.00 08/30/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 654242501
Principal investigator 1 AbbVie, Inc. $6,265.20 08/29/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-533 No dispute reported 06/30/2026 647584367
Recipient Eli Lilly and Company $522.53 08/27/2019 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) No dispute reported 06/30/2026 654281899
Principal investigator 1 AbbVie, Inc. $28,318.42 08/08/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-234 No dispute reported 06/30/2026 647584441
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,250.00 08/08/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
EntyvioVedolizumab Long Term Study No dispute reported 06/30/2026 686168657
Principal investigator 1 AbbVie, Inc. $2,165.00 07/30/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-430 No dispute reported 06/30/2026 647584433
Principal investigator 1 Janssen Research & Development, LLC $12,671.00 07/26/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 654242497
Principal investigator 1 Janssen Research & Development, LLC $16,349.00 07/25/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 654243295
Principal investigator 1 Janssen Research & Development, LLC $2,176.00 07/23/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 654243297
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 07/23/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 654243299
Principal investigator 1 Janssen Research & Development, LLC $3,708.00 07/23/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 654243301
Principal investigator 1 Gilead Sciences, Inc. $1,350.00 07/17/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 676494303
Principal investigator 1 Gilead Sciences, Inc. $1,390.00 07/17/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 676494311
Principal investigator 1 AbbVie, Inc. $90.00 07/02/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-533 No dispute reported 06/30/2026 647584435
Principal investigator 1 AbbVie, Inc. $2,900.75 07/02/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-430 No dispute reported 06/30/2026 647584437
Principal investigator 1 AbbVie, Inc. $2,705.20 07/01/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-234 No dispute reported 06/30/2026 647584439
Principal investigator 1 Janssen Research & Development, LLC $8,046.00 06/28/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 654242495
Principal investigator 1 Janssen Research & Development, LLC $2,720.00 06/28/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists
Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis No dispute reported 06/30/2026 654243279
Principal investigator 1 AbbVie, Inc. $536.25 06/27/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-431 No dispute reported 06/30/2026 647584431
Principal investigator 1 AbbVie, Inc. $1,450.00 06/24/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-430 No dispute reported 06/30/2026 647584429
Principal investigator 1 Genentech, Inc. $1,344.60 06/17/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
OLE No dispute reported 06/30/2026 681092299
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $173.70 06/14/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
SC P3 CD Study No dispute reported 06/30/2026 686168655
Principal investigator 1 Eli Lilly and Company $11,037.60 06/12/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 654288431
Principal investigator 1 AbbVie, Inc. $545.58 05/29/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-234 No dispute reported 06/30/2026 647584413
Principal investigator 1 AbbVie, Inc. $30,231.08 05/29/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-234 No dispute reported 06/30/2026 647584415
Principal investigator 1 AbbVie, Inc. $2,963.25 05/29/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-430 No dispute reported 06/30/2026 647584419
Principal investigator 1 AbbVie, Inc. $7,813.75 05/29/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-431 No dispute reported 06/30/2026 647584423
Principal investigator 1 AbbVie, Inc. $1,453.20 05/28/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-533 No dispute reported 06/30/2026 647584425
Principal investigator 1 Janssen Research & Development, LLC $21,857.00 05/27/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 654242491
Principal investigator 1 Gilead Sciences, Inc. $1,294.00 05/22/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 676494297
Principal investigator 1 Eli Lilly and Company $20.00 05/09/2019 Non-covered Recipient Entity
NORTH COUNTY GASTROENTEROLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 654293161
Principal investigator 1 AbbVie, Inc. $4,258.25 05/03/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-430 No dispute reported 06/30/2026 647584421
Principal investigator 1 AbbVie, Inc. $1,196.36 05/02/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-234 No dispute reported 06/30/2026 647584417
Principal investigator 1 AbbVie, Inc. $1,189.20 05/02/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-533 No dispute reported 06/30/2026 647584427
Principal investigator 1 PFIZER INC. $682.81 05/01/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 671619903
Principal investigator 1 AbbVie, Inc. $9,006.75 04/29/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-431 No dispute reported 06/30/2026 647584411
Principal investigator 1 Janssen Research & Development, LLC $10,096.00 04/29/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 654242493
Principal investigator 1 Janssen Research & Development, LLC $10,901.00 04/25/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 654243289
Principal investigator 1 Janssen Research & Development, LLC $7,416.00 04/25/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 654243291
Principal investigator 1 Janssen Research & Development, LLC $3,489.00 04/25/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 654243293
Principal investigator 1 Gilead Sciences, Inc. $1,656.00 04/17/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 676494289
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 04/17/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 676494293
Principal investigator 1 AbbVie, Inc. $3,787.00 03/29/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-431 No dispute reported 06/30/2026 647584407
Principal investigator 1 AbbVie, Inc. $457.20 03/27/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-533 No dispute reported 06/30/2026 647584401
Principal investigator 1 AbbVie, Inc. $875.00 03/26/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-430 No dispute reported 06/30/2026 647584403
Recipient Eli Lilly and Company $1,091.45 03/26/2019 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 654281897
Principal investigator 1 AbbVie, Inc. $2,342.96 03/25/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-234 No dispute reported 06/30/2026 647584405
Principal investigator 1 Janssen Research & Development, LLC $19,282.00 03/25/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 654242489
Principal investigator 1 Gilead Sciences, Inc. $2,730.00 03/20/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 676494279
Principal investigator 1 Gilead Sciences, Inc. $14,535.00 03/20/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 676494285
Principal investigator 1 Genentech, Inc. $1,080.90 03/18/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
OLE No dispute reported 06/30/2026 681081659
Principal investigator 1 PFIZER INC. $59,736.00 03/06/2019 Non-covered Recipient Entity
Atlanta Gastro Specialists
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 671695371
Principal investigator 1 AbbVie, Inc. $3,144.40 02/28/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-533 No dispute reported 06/30/2026 647584387
Principal investigator 1 AbbVie, Inc. $513.25 02/28/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-430 No dispute reported 06/30/2026 647584391
Principal investigator 1 AbbVie, Inc. $7,573.84 02/28/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-234 No dispute reported 06/30/2026 647584393
Principal investigator 1 AbbVie, Inc. $18,809.75 02/28/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-431 No dispute reported 06/30/2026 647584395
Principal investigator 1 PFIZER INC. $920.31 02/13/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 671695235
Principal investigator 1 AbbVie, Inc. $308.80 02/08/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-431 No dispute reported 06/30/2026 647584399
Principal investigator 1 Celgene Corporation $961.25 02/05/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY
A Randomized, double-blind, multicenter study to explore the effect of GED-0301 on endoscopic and clinical outcomes in subjects with active Crohn’s disease. (GED-0301-CD-001) No dispute reported 06/30/2026 675416145
Principal investigator 1 AbbVie, Inc. $6,810.60 02/01/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-533 No dispute reported 06/30/2026 647584389
Principal investigator 1 AbbVie, Inc. $15,096.00 02/01/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-234 No dispute reported 06/30/2026 647584397
Principal investigator 1 AbbVie, Inc. $19,472.00 01/29/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
M14-431 No dispute reported 06/30/2026 647584409
Principal investigator 1 Gilead Sciences, Inc. $1,350.00 01/28/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease No dispute reported 06/30/2026 676494269
Principal investigator 1 Gilead Sciences, Inc. $1,390.00 01/28/2019 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 676494275
Principal investigator 1 Janssen Research & Development, LLC $6,434.00 01/24/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 654243285
Principal investigator 1 Janssen Research & Development, LLC $8,977.00 01/24/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 654243287
Principal investigator 1 Janssen Research & Development, LLC $2,650.00 01/17/2019 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 654243283